Fresenius SE & Co. KGaA / Key word(s): Miscellaneous
Fresenius SE & Co. KGaA: Fresenius expects meaningful positive effects from US tax reform
22-Dec-2017 / 21:51 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Fresenius expects meaningful positive effects from US tax reform
Fresenius expects meaningful positive effects from the tax reform legislation signed into law in the United States today. The new law goes into effect on January 1, 2018.
The new legislation triggers the revaluation of deferred tax liabilities. This results in a one-time book gain of approximately EUR 90 million, to be reflected in Fresenius’ 2017 Group net income*. Thereof, approximately EUR 30 million are attributable to Fresenius Kabi and approximately EUR 60 million** to Fresenius Medical Care.
Fresenius will report FY17 results and provide FY18 guidance, including details on recurring tax effects resulting from the US tax reform, on February 27, 2018.
Fresenius SE & Co. KGaA,
Bad Homburg v.d.H., 22 December 2017
* Net income attributable to shareholders of Fresenius SE & Co. KGaA
22-Dec-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Fresenius SE & Co. KGaA|
|61352 Bad Homburg v.d.H.|
|Phone:||+49 (0)6172 608-2485|
|Fax:||+49 (0)6172 608-2488|
|Listed:||Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxemburg|
|End of Announcement||DGAP News Service|